CN114344455A - Preparation method and application of anti-aging composition - Google Patents
Preparation method and application of anti-aging composition Download PDFInfo
- Publication number
- CN114344455A CN114344455A CN202210062269.7A CN202210062269A CN114344455A CN 114344455 A CN114344455 A CN 114344455A CN 202210062269 A CN202210062269 A CN 202210062269A CN 114344455 A CN114344455 A CN 114344455A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- stirring
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930187479 gypenoside Natural products 0.000 claims abstract description 9
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 claims abstract description 9
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 18
- 239000011812 mixed powder Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 11
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 230000009758 senescence Effects 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000008485 antagonism Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 231100000915 pathological change Toxicity 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method and application of a composition for delaying senility, belonging to the technical field of preparation methods of health-care medicines, and the composition comprises 5 to 20 parts of beta-Nicotinamide Mononucleotide (NMN) and super dismutase (SOD): 1 to 10 parts, gypenoside: 1 to 10 parts of pyrroloquinoline quinone (PQQ): 1 to 10 parts, the invention has the following beneficial effects: the anti-aging health product is prepared by screening the traditional Chinese medicine which has obvious antagonism on the pathological changes through modern pharmacological tests, scientifically composing and developing, and can be frequently eaten by people.
Description
Technical Field
The invention relates to the technical field of preparation methods of health-care medicines, in particular to a preparation method and application of a composition for delaying senescence.
Background
Aging is a natural process manifested by a decline in structure and function, and a decline in adaptability and resistance. According to the statistics of relevant data, in recent years, the middle-aged people of about 40 years old suffer from cardiovascular and cerebrovascular diseases such as myocardial infarction and cerebral hemorrhage, and the incidence of diseases such as coronary heart disease, hypertension, hyperlipidemia, diabetes and the like tends to be younger. The reasons for this are mainly: under the double pressure of work and life, the young and middle-aged people excessively consume and penetrate the physical energy of the branch, so that the tissues and organs are aged in advance. With the improvement of living standard of people, people continuously seek methods for prolonging life, improving immunity, overcoming various diseases and improving body functions so as to improve life quality. Therefore, the development of the health care product with anti-aging function and homology of medicine and food is needed continuously.
Therefore, the preparation method and the application of the anti-aging composition are needed.
Disclosure of Invention
In order to achieve the above purpose, the invention provides the following technical scheme: a process for preparing the composition for delaying senility and its application, which contains beta-Nicotinamide Mononucleotide (NMN) 5-20 weight portions, super dismutase (SOD): 1 to 10 parts, gypenoside: 1 to 10 parts of pyrroloquinoline quinone (PQQ): 1 to 10 parts, and the specific steps are as follows:
s1: fully crushing the components into powder;
s2: pouring powder of beta-Nicotinamide Mononucleotide (NMN) into a stirrer, and stirring;
s3: pouring the powder of the superoxide dismutase (SOD) into a stirrer in S2, and stirring;
s4: pouring the powder of the gypenoside into a stirrer in S3, and stirring;
s5: then pouring the powder of pyrroloquinoline quinone (PQQ) into a stirrer in S4, and stirring;
s6: mixing the components, and uniformly stirring to obtain mixed powder;
s7: weighing the weight M of the mixed powder, and calculating to obtain the weight N of the mixed powder in each capsule;
s8: the mixed powder was weighed out by a balance to obtain a weighed amount of N, and the weighed amount was filled into capsules.
As a preferable scheme of the preparation method and the application of the anti-aging composition, the anti-aging composition comprises the following components: the parts of the above components are by weight.
As a preferable scheme of the preparation method and the application of the anti-aging composition, the anti-aging composition comprises the following components: the stirring described in steps S2-S6 is continued.
As a preferable scheme of the preparation method and the application of the anti-aging composition, the anti-aging composition comprises the following components: steps S1-S8 are performed in a sterile environment.
As a preferable scheme of the preparation method and the application of the anti-aging composition, the anti-aging composition comprises the following components: and step S11, adding microcrystalline cellulose and magnesium stearate into the mixed powder with the weight of N to prepare the tabletting candy.
The invention has the beneficial effects that: the anti-aging health product is prepared by screening the traditional Chinese medicine which has obvious antagonism on the pathological changes through modern pharmacological tests, scientifically composing and developing, and can be frequently eaten by people.
Detailed Description
The following description of the preferred embodiments of the present invention is provided for the purpose of illustration and description, and is in no way intended to limit the invention.
The invention provides a preparation method and application of a composition for delaying senility, which comprises 5 to 20 parts of beta-Nicotinamide Mononucleotide (NMN) and super dismutase (SOD): 1 to 10 parts, gypenoside: 1 to 10 parts of pyrroloquinoline quinone (PQQ): 1 to 10 parts, and the specific steps are as follows:
s1: fully crushing the components into powder;
s2: pouring powder of beta-Nicotinamide Mononucleotide (NMN) into a stirrer, and stirring;
s3: pouring the powder of the superoxide dismutase (SOD) into a stirrer in S2, and stirring;
s4: pouring the powder of the gypenoside into a stirrer in S3, and stirring;
s5: then pouring the powder of pyrroloquinoline quinone (PQQ) into a stirrer in S4, and stirring;
s6: mixing the components, and uniformly stirring to obtain mixed powder;
s7: weighing the weight M of the mixed powder, and calculating to obtain the weight N of the mixed powder in each capsule;
s8: weighing the mixed powder with the weight of N by using a balance, and filling the mixed powder into capsules;
the above components are mixed in parts by weight, the stirring in steps S2-S6 is carried out all the time, and the steps S1-S8 are carried out in a sterile environment.
And step S11, adding microcrystalline cellulose and magnesium stearate into the mixed powder with the weight of N to prepare the tabletting candy.
Example 1:
the composition is prepared from the following raw material medicines in parts by weight, 5 parts of beta-Nicotinamide Mononucleotide (NMN) and super dismutase (SOD): 1 part, gypenoside: 1 part, pyrroloquinoline quinone (PQQ): 1 part.
Example 2:
20 parts of beta-Nicotinamide Mononucleotide (NMN) and super dismutase (SOD): 10 parts of gypenoside: 10 parts of pyrroloquinoline quinone (PQQ): 10 parts.
The raw materials are mixed uniformly according to the proportion and then prepared into capsules or added with microcrystalline cellulose and magnesium stearate to prepare tabletting candies.
The above is only a preferred embodiment of the present invention, and any person skilled in the art may modify the present invention or modify it into an equivalent technical solution by using the technical solution described above. Therefore, any simple modifications or equivalent substitutions made in accordance with the technical solution of the present invention are within the scope of the claims of the present invention.
Claims (5)
1. A preparation method and application of a composition for delaying senescence are characterized by comprising 5 to 20 parts of beta-Nicotinamide Mononucleotide (NMN) and super dismutase (SOD): 1 to 10 parts, gypenoside: 1 to 10 parts of pyrroloquinoline quinone (PQQ): 1 to 10 parts, and the specific steps are as follows:
s1: fully crushing the components into powder;
s2: pouring powder of beta-Nicotinamide Mononucleotide (NMN) into a stirrer, and stirring;
s3: pouring the powder of the superoxide dismutase (SOD) into a stirrer in S2, and stirring;
s4: pouring the powder of the gypenoside into a stirrer in S3, and stirring;
s5: then pouring the powder of pyrroloquinoline quinone (PQQ) into a stirrer in S4, and stirring;
s6: mixing the components, and uniformly stirring to obtain mixed powder;
s7: weighing the weight M of the mixed powder, and calculating to obtain the weight N of the mixed powder in each capsule;
s8: the mixed powder was weighed out by a balance to obtain a weighed amount of N, and the weighed amount was filled into capsules.
2. The method for preparing a composition for delaying aging as claimed in claim 1, wherein the parts of the above components are by weight.
3. The method for preparing antiaging composition as claimed in claim 1, wherein the stirring in steps S2-S6 is performed.
4. The method for preparing the antiaging composition as claimed in claim 1, wherein the steps S1-S8 are performed in a sterile environment.
5. The preparation method and the application of the composition for delaying senescence of claim 1, wherein the mixed powder with the weight of N in the step S11 is added with microcrystalline cellulose and magnesium stearate to prepare the tabletting candy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210062269.7A CN114344455A (en) | 2022-01-19 | 2022-01-19 | Preparation method and application of anti-aging composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210062269.7A CN114344455A (en) | 2022-01-19 | 2022-01-19 | Preparation method and application of anti-aging composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114344455A true CN114344455A (en) | 2022-04-15 |
Family
ID=81090801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210062269.7A Pending CN114344455A (en) | 2022-01-19 | 2022-01-19 | Preparation method and application of anti-aging composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114344455A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075412A (en) * | 2016-07-29 | 2016-11-09 | 陈石良 | A kind of antioxidation SOD compound enzyme capsule and preparation method thereof |
| US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
| US20180071273A1 (en) * | 2015-03-17 | 2018-03-15 | Speccialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| CN109350622A (en) * | 2018-10-17 | 2019-02-19 | 深圳市龙格生技术有限公司 | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt |
| CN109394850A (en) * | 2018-12-17 | 2019-03-01 | 温州古木生物科技有限公司 | It is a kind of to have effects that the Chinese medicine composition of delay skin aging and its water extract and fermentation material and application |
| US20210220422A1 (en) * | 2020-01-20 | 2021-07-22 | Jonathan Parker | Dietary supplement compositions and methods |
| CN113170889A (en) * | 2021-05-21 | 2021-07-27 | 卢静 | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof |
-
2022
- 2022-01-19 CN CN202210062269.7A patent/CN114344455A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170266213A1 (en) * | 2015-03-16 | 2017-09-21 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products |
| US20180071273A1 (en) * | 2015-03-17 | 2018-03-15 | Speccialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| CN106075412A (en) * | 2016-07-29 | 2016-11-09 | 陈石良 | A kind of antioxidation SOD compound enzyme capsule and preparation method thereof |
| CN109350622A (en) * | 2018-10-17 | 2019-02-19 | 深圳市龙格生技术有限公司 | The group technology of niacinamide core carbohydrates and their derivative and pyrroloquinoline quinone and its sodium salt |
| CN109394850A (en) * | 2018-12-17 | 2019-03-01 | 温州古木生物科技有限公司 | It is a kind of to have effects that the Chinese medicine composition of delay skin aging and its water extract and fermentation material and application |
| US20210220422A1 (en) * | 2020-01-20 | 2021-07-22 | Jonathan Parker | Dietary supplement compositions and methods |
| CN113170889A (en) * | 2021-05-21 | 2021-07-27 | 卢静 | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 郑建仙主编: "《植物活性成分开发》", 中国轻工业出版社, pages: 292 - 295 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101731622A (en) | Lucid ganoderma spirulina tablet and preparation process thereof | |
| CN101837032A (en) | Blueberry anthocyanin oral solution | |
| CN104705652A (en) | Soft capsule with anti-oxidation function and preparation method of soft capsule | |
| CN110301640A (en) | Bitter buckwheat flavone dry powder and its preparation have auxiliary hyperglycemic function health care product purposes | |
| CN108851063A (en) | A kind of Co-Q10 natural vitamin E soft capsule and preparation method thereof | |
| CN101991786A (en) | Formula of medicine for reducing blood fat and preparations thereof | |
| CN114344455A (en) | Preparation method and application of anti-aging composition | |
| CN106727676A (en) | A kind of replenish the calcium composition and its application for reducing hypercalcemia risk | |
| CN107595798B (en) | Prucalopride succinate tablet and preparation method thereof | |
| CN103550398A (en) | Composition for relieving fatigue as well as preparation method and medical application thereof | |
| CN109906084A (en) | A kind of replenish the calcium composition and its application reducing hypercalcemia risk | |
| CN101214275B (en) | Compound red sage root extended release formulation and preparation thereof | |
| CN109349490A (en) | A kind of solid drinks and preparation method thereof with the sugared function of polysaccharide of control | |
| CN103931995A (en) | Chondroitin sulfate calcium tablet capable of increasing bone density and preparation method of chondroitin sulfate calcium tablet | |
| CN1377702A (en) | Lucid ganoderma wall-breaking spore powder capsule | |
| CN102018208A (en) | Laver nut crisp and processing technology thereof | |
| CN1803182A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN113456639A (en) | Anti-arrhythmia pharmaceutical composition and preparation method thereof | |
| CN111481519A (en) | Production process of isosorbide mononitrate tablets | |
| CN101015345A (en) | Health-care food with hypoxia-resistant and immunity-enhancing functions and its preparing process | |
| CN106580909A (en) | Solid drug composition containing sarpogrelate hydrochloride | |
| CN104940164B (en) | A kind of Acarbose capsules agent medicine compositions and preparation method thereof | |
| CN1813886B (en) | Chinese medicine formulation for activating blood flow and removing blood stasis and stopping pain, and its preparing method | |
| CN100402060C (en) | Heart beneficial keton dispersion tablet and its preparation method | |
| CN107173804A (en) | Ginkgo leaf purple perilla soft capsule and processing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220415 |
|
| RJ01 | Rejection of invention patent application after publication |